JARDI-ASH 25 MG TABLET contains Empagliflozin 25 mg, an SGLT2 inhibitor used with diet and exercise for type 2 diabetes and, when prescribed, heart and kidney protection.
Product Summary
JARDI-ASH 25 MG TABLET contains Empagliflozin 25 mg, an oral Sodium-Glucose Cotransporter-2 (SGLT2) inhibitor. It is used as part of an appropriate treatment plan for type 2 diabetes mellitus and may also be prescribed for certain heart failure and chronic kidney disease indications, depending on the patient's clinical status and applicable prescribing information. Empagliflozin works through the kidneys to increase urinary glucose excretion while also producing beneficial effects on fluid and sodium handling.
JARDI-ASH 25 MG TABLET contains Empagliflozin 25 mg, an SGLT2 inhibitor used in metabolic, cardiovascular, and renal care.
It reduces glucose reabsorption in the kidneys, increasing glucose elimination through urine.
This mechanism helps lower blood glucose in adults and eligible pediatric patients with type 2 diabetes.
Empagliflozin is also indicated in adults with symptomatic chronic heart failure and certain chronic kidney disease populations under current prescribing guidance.
The 25 mg strength is generally used when additional glycemic control is required after assessment of the patient's response to therapy.
Treatment should be individualized and monitored by a qualified healthcare professional.
Usage Instructions
Take JARDI-ASH 25 MG TABLET exactly as prescribed by your healthcare provider.
The usual administration is once daily in the morning, with or without food, when this regimen is prescribed.
Swallow the tablet whole with water.
Maintain adequate fluid intake according to your healthcare provider's advice.
Do not increase or decrease the dose without medical guidance.
If a dose is missed, take it when remembered unless it is close to the next scheduled dose; do not double the next dose.
Medicinal Advantages
Helps improve glycemic control in type 2 diabetes mellitus when used alongside diet and exercise.
Promotes urinary glucose excretion through an insulin-independent mechanism.
The empagliflozin class has established cardiovascular benefits in appropriate patients.
It is indicated for reducing cardiovascular death in certain adults with type 2 diabetes and established cardiovascular disease.
Current prescribing information also includes treatment of symptomatic chronic heart failure in adults.
It is indicated for certain adults with chronic kidney disease at risk of progression.
Mechanism of Action
Empagliflozin selectively inhibits SGLT2, a transporter located primarily in the proximal renal tubules. SGLT2 normally reabsorbs filtered glucose back into the bloodstream. By inhibiting this transporter, empagliflozin reduces renal glucose reabsorption and increases glucose excretion in urine.
SGLT2 inhibition also increases sodium excretion and produces an osmotic diuretic effect. These changes contribute to its glucose-lowering action and are part of the pharmacological basis for its cardiovascular and kidney benefits in appropriate patients.
Off-Label Uses
Empagliflozin should be used according to an approved indication and the prescribing information applicable to the patient and country. Off-label use should only be considered by a qualified healthcare professional when there is an appropriate clinical rationale.
Because approved indications for empagliflozin have expanded to include specific cardiovascular and kidney conditions, uses should not automatically be described as off-label without checking the current local product information.
Expert Advice
Take the medicine consistently according to the prescribed schedule.
Kidney function should be assessed before initiation and monitored when clinically appropriate.
Your healthcare provider should assess hydration/volume status before treatment and address significant volume depletion where necessary.
Tell your doctor about other diabetes medicines, diuretics, and all prescription or non-prescription products you use.
If surgery or a procedure involving prolonged fasting is planned, discuss the medicine with your healthcare provider; current U.S. prescribing information recommends withholding empagliflozin for at least 3 days beforehand when possible.
Continue diet, exercise, glucose monitoring, and other measures included in your individualized diabetes-care plan.
Precautions
1. Assess Kidney Function
Kidney function should be assessed before starting treatment and periodically when clinically appropriate. The suitability of empagliflozin depends partly on renal function and the indication being treated.
2. Maintain Appropriate Hydration
Because SGLT2 inhibition increases urinary glucose and fluid loss, your healthcare provider may assess volume status before treatment and advise appropriate fluid intake.
3. Type 1 Diabetes Is Not an Approved Glycemic-Control Use
Empagliflozin is not recommended for improving glycemic control in patients with type 1 diabetes because of the risk of diabetic ketoacidosis.
4. Surgery and Prolonged Fasting
Tell your healthcare provider before surgery or procedures involving prolonged fasting. Current prescribing information recommends temporarily withholding the medicine for at least 3 days beforehand when possible.
5. Review Other Medicines
Inform your healthcare provider about all medicines you take, particularly other glucose-lowering medicines and drugs that affect fluid balance, so your overall treatment can be appropriately coordinated.
Storage Conditions
Store at approximately 25°C under controlled room-temperature conditions.
Permitted temperature excursions are generally 15°C–30°C according to the cited product labeling.
Protect the tablets from excessive heat and moisture.
Keep them in their original packaging until use.
Keep out of reach of children.
Do not use after the expiry date printed on the package.
Frequently Asked Questions (FAQs)
1. What is JARDI-ASH 25 MG TABLET?
It is a tablet containing Empagliflozin 25 mg, an SGLT2 inhibitor used in the management of type 2 diabetes and, where indicated, certain cardiovascular and kidney conditions.
2. What is JARDI-ASH 25 MG TABLET used for?
Empagliflozin is used with diet and exercise to improve glycemic control in type 2 diabetes. Current prescribing information also includes specific heart failure and chronic kidney disease indications.
3. How does Empagliflozin work?
It blocks SGLT2 in the kidneys, reducing glucose reabsorption and increasing glucose elimination through urine.
4. How is the 25 mg strength generally taken?
Empagliflozin is generally taken once daily in the morning, with or without food. The 25 mg dose may be used for additional glycemic control in appropriate patients after assessment of the 10 mg dose.
5. Can JARDI-ASH 25 MG TABLET be taken with food?
Yes. Empagliflozin can be taken with or without food.
6. Is JARDI-ASH 25 MG TABLET used for heart failure?
Empagliflozin is indicated for the treatment of symptomatic chronic heart failure in adults under current prescribing information.
7. Is Empagliflozin used for chronic kidney disease?
Yes. Current prescribing information includes an indication for certain adults with chronic kidney disease who are at risk of progression.
8. What should I do if I miss a dose?
Take the missed dose when remembered, unless it is close to the next scheduled dose. Do not take two doses together.
9. Is JARDI-ASH 25 MG TABLET a prescription medicine?
Empagliflozin products are prescription medicines and should be used under appropriate medical supervision.
Suggested Product Tags
JARDI-ASH 25 MG TABLET
Empagliflozin 25 mg Tablet
Empagliflozin 25 mg
SGLT2 Inhibitor
SGLT2 Diabetes Medicine
Type 2 Diabetes Medicine
Diabetes Management
Blood Sugar Control
Empagliflozin Tablet
Oral Diabetes Medication
Cardiovascular Medicine
Heart Failure Treatment
Chronic Kidney Disease Medicine
Renal Protection
Prescription Diabetes Medicine
SGLT2 Inhibitor Tablet
Empagliflozin Prescription
Type 2 Diabetes Treatment
Kidney Health Medicine
Cardiometabolic Medicine
